Home/Pipeline/AIM-HI-UC

AIM-HI-UC

Ulcerative Colitis

Clinical TrialsActive

Key Facts

Indication

Ulcerative Colitis

Phase

Clinical Trials

Status

Active

Company

PathAI

About PathAI

PathAI is a leading AI-powered pathology company that has developed a comprehensive platform, AISight®, for digital pathology image management and AI algorithm deployment. It serves two primary markets: biopharma clients, for whom it provides translational research, clinical trial services, and diagnostic development, and anatomic pathology laboratories, which use its platform for workflow digitization and AI-assisted diagnostics. The company has achieved significant regulatory milestones, including FDA clearance for its AISight® Dx platform for primary diagnosis and FDA qualification for its AIM-MASH tool for clinical trials, and collaborates with major industry players like Labcorp and top biopharma firms.

View full company profile

Therapeutic Areas

Oncology Gastrointestinal & Liver Diseases (MASH, IBD)Dermatology

Other Ulcerative Colitis Drugs

Drug	Company	Phase	Status
BB265	BiomeBank	Phase 1	Active
PALI-2108	Palisade Bio	Phase 2	Advancing towards initiation
ALTB-268	AltruBio	Phase IIa	Active
Patient Stratification in Ulcerative Colitis	Enable Medicine	Research	Active
Mesalazine (Lifecycle Management)	Dr. Falk Pharma	Approved/Phase 3	Active
AhR Agonist Program	Azora Therapeutics	Phase 1b	Active
R-3750	Virtici	Phase 1	Active
GPR35 Inhibitor	ThirtyFiveBio	Preclinical	Active
BT-600	Biora Therapeutics	Phase 1	Active
Asacol® (mesalazine)	Tillotts Pharma	Approved	Active
MB310	Microbiotica	Phase 1b	Active
'1805	Revolo Biotherapeutics	Phase 2 (Planned)	Active